Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Active not recruiting 1

Sponsor Class

OTHER 2NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms 2Malignant Solid Neoplasm 2Colorectal Neoplasms 2Rectal Neoplasms 1Pain 1Neoplasm Metastasis 1Lymphoma, B-Cell 1Hematopoietic and Lymphatic System Neoplasm 1Hematologic Neoplasms 1Fatigue 1Colonic Neoplasms 1Burkitt Lymphoma 1Breast Neoplasms 1Breast Carcinoma In Situ 1Acquired Immunodeficiency Syndrome 1

Interventions

Radiotherapy 9Radiosurgery 6Oxaliplatin 5Cisplatin 5Paclitaxel 4Capecitabine 4Leucovorin 3Irinotecan 3Fluorouracil 3Doxorubicin 3Docetaxel 3strontium chloride 2regorafenib 2pembrolizumab 2enzalutamide 2Zoledronic Acid 2Temozolomide 2Radiofrequency Ablation 2Mitomycin 2Methods 2Ifosfamide 2Gemcitabine 2Filgrastim 2Educational Status 2Early Intervention, Educational 2Bleomycin 2Bevacizumab 2Analgesia 2Albumin-Bound Paclitaxel 2trifluridine tipiracil drug combination 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Neoplasm Metastasis × Interviews as Topic × Clear all
NCT05455606 2026-01-22

Does the Use of a Genomic Tumor Board Increase the Number of Patients Who Receive Genome-Informed Treatment

SWOG Cancer Research Network

Phase NA Active not recruiting
1,284 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡